CA3172641A1 - Masked il-12 cytokines and their cleavage products - Google Patents
Masked il-12 cytokines and their cleavage products Download PDFInfo
- Publication number
- CA3172641A1 CA3172641A1 CA3172641A CA3172641A CA3172641A1 CA 3172641 A1 CA3172641 A1 CA 3172641A1 CA 3172641 A CA3172641 A CA 3172641A CA 3172641 A CA3172641 A CA 3172641A CA 3172641 A1 CA3172641 A1 CA 3172641A1
- Authority
- CA
- Canada
- Prior art keywords
- cytokine
- masked
- seq
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063003842P | 2020-04-01 | 2020-04-01 | |
| US63/003,842 | 2020-04-01 | ||
| US202063118579P | 2020-11-25 | 2020-11-25 | |
| US63/118,579 | 2020-11-25 | ||
| US202063127893P | 2020-12-18 | 2020-12-18 | |
| US63/127,893 | 2020-12-18 | ||
| PCT/US2021/025107 WO2021202678A1 (en) | 2020-04-01 | 2021-03-31 | Masked il-12 cytokines and their cleavage products |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3172641A1 true CA3172641A1 (en) | 2021-10-07 |
Family
ID=77929928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3172641A Pending CA3172641A1 (en) | 2020-04-01 | 2021-03-31 | Masked il-12 cytokines and their cleavage products |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230159603A1 (https=) |
| EP (1) | EP4126249A4 (https=) |
| JP (2) | JP7771076B2 (https=) |
| KR (1) | KR20220161405A (https=) |
| CN (1) | CN115734806A (https=) |
| AU (1) | AU2021248919A1 (https=) |
| BR (1) | BR112022019708A2 (https=) |
| CA (1) | CA3172641A1 (https=) |
| IL (1) | IL296913A (https=) |
| MX (1) | MX2022012312A (https=) |
| PH (1) | PH12022552632A1 (https=) |
| TW (1) | TWI906278B (https=) |
| WO (1) | WO2021202678A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111630062A (zh) | 2017-11-28 | 2020-09-04 | 中外制药株式会社 | 具有可调节的配体结合活性的配体结合分子 |
| CA3100005A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| AU2019271148B9 (en) | 2018-05-14 | 2025-05-29 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
| CN120463822A (zh) | 2018-09-27 | 2025-08-12 | 西里欧发展公司 | 掩蔽型细胞因子多肽 |
| KR20220023988A (ko) | 2019-05-14 | 2022-03-03 | 웨어울프 세라퓨틱스, 인크. | 분리 모이어티 및 이의 사용 방법 |
| BR112022009110A2 (pt) | 2019-11-14 | 2022-07-26 | Werewolf Therapeutics Inc | Polipeptídeos de citocina ativáveis e métodos de uso destes |
| AU2021254283B2 (en) | 2020-04-10 | 2025-12-11 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| WO2022115865A2 (en) * | 2020-11-25 | 2022-06-02 | Xilio Development, Inc. | Tumor-specific cleavable linkers |
| JP2024511387A (ja) * | 2021-03-16 | 2024-03-13 | シートムエックス セラピューティクス，インコーポレイテッド | マスクした活性化可能サイトカイン構成体ならびに関連する組成物及び方法 |
| TW202321282A (zh) | 2021-07-19 | 2023-06-01 | 美商再生元醫藥公司 | Il12受體促效劑及其使用方法 |
| WO2023161853A1 (en) | 2022-02-23 | 2023-08-31 | Bright Peak Therapeutics Ag | Activatable il-18 polypeptides |
| MX2024010488A (es) * | 2022-02-28 | 2024-09-05 | Xilio Dev Inc | Citocinas dirigidas y metodos de uso de estas. |
| WO2023220501A1 (en) * | 2022-05-12 | 2023-11-16 | Massachusetts Institute Of Technology | Activatable therapeutic peptides and uses thereof |
| US20260035434A1 (en) * | 2022-08-01 | 2026-02-05 | Ose Immunotherapeutics | Heterodimeric fc-clec-1 fusion molecule and uses thereof |
| CN117917438A (zh) * | 2022-10-21 | 2024-04-23 | 北京诺诚健华医药科技有限公司 | 抗体融合蛋白及其制备和应用 |
| US20240417436A1 (en) | 2023-01-11 | 2024-12-19 | Bright Peak Therapeutics Ag | Conditionally activated immunocytokines and methods of use |
| WO2024150175A1 (en) | 2023-01-11 | 2024-07-18 | Bright Peak Therapeutics Ag | Conditionally activated proteins and methods of use |
| CR20250279A (es) * | 2023-01-20 | 2025-08-25 | Boehringer Ingelheim Int | Proteínas de fusión fc de il-12 |
| EP4695281A1 (en) * | 2023-04-12 | 2026-02-18 | CytomX Therapeutics, Inc. | Masking polypeptides, activatable cytokine constructs, and related compositions and methods |
| WO2024216146A1 (en) * | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Masking polypeptides, activatable cytokine constructs, and related compositions and methods |
| CN121263432A (zh) * | 2023-04-12 | 2026-01-02 | 上海康抗生物技术有限公司 | 包含掩蔽型白介素12的多功能分子及使用方法 |
| WO2025041101A1 (en) | 2023-08-23 | 2025-02-27 | Bright Peak Therapeutics Ag | Activatable il-18 immunocytokines and uses thereof |
| WO2025119304A1 (en) * | 2023-12-07 | 2025-06-12 | Wuxi Biologics (Shanghai) Co., Ltd. | Heterodimeric proteins against il-12 receptor |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1489100B1 (en) * | 1997-12-08 | 2016-06-15 | Merck Patent GmbH | Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
| BRPI0620648B1 (pt) * | 2005-12-30 | 2022-12-20 | Merck Patent Gesellschaft Mit Beschrãnkter Haftung | Variante de il-12 p40, proteínas il-12, il-23 e de fusão, composição farmacêutica e uso da mesma |
| AU2013381970A1 (en) * | 2013-03-15 | 2015-10-22 | Carnegie Mellon University | Linked peptide fluorogenic biosensors |
| MA41374A (fr) * | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| CN108112254B (zh) * | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| JP7358047B2 (ja) * | 2016-05-16 | 2023-10-10 | チェックマブ エス．アール．エル． | 腫瘍浸潤制御性ｔ細胞において選択的に脱制御されたマーカー |
| MX2019004775A (es) * | 2016-11-03 | 2019-08-05 | Squibb Bristol Myers Co | Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) activables y sus usos. |
| CN111527109B (zh) * | 2017-12-26 | 2024-11-01 | 南京金斯瑞生物科技有限公司 | 以抗体Fc区为骨架的融合蛋白二聚体及其应用 |
| CN108218993B (zh) * | 2018-01-05 | 2020-11-17 | 阿思科力(苏州)生物科技有限公司 | 一种以robo1为靶点的双特异性抗体及其制备和应用 |
| WO2019173832A2 (en) * | 2018-03-09 | 2019-09-12 | AskGene Pharma, Inc. | Novel cytokine prodrugs |
| CN110396133B (zh) | 2018-04-25 | 2021-07-23 | 免疫靶向有限公司 | 一种以白介素12为活性成分的融合蛋白型药物前体 |
| CA3100005A1 (en) * | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| EP3810624A4 (en) * | 2018-06-22 | 2022-07-06 | Cugene Inc. | Cytokine-based bioactivatable drugs and methods of uses thereof |
| US12459980B2 (en) * | 2018-07-25 | 2025-11-04 | AskGene Pharma, Inc. | IL-21 prodrugs and methods of use thereof |
| CN120463822A (zh) * | 2018-09-27 | 2025-08-12 | 西里欧发展公司 | 掩蔽型细胞因子多肽 |
| EP3861016A2 (en) * | 2018-10-03 | 2021-08-11 | Xencor, Inc. | Il-12 heterodimeric fc-fusion proteins |
| US20220356221A1 (en) * | 2019-09-28 | 2022-11-10 | AskGene Pharma, Inc. | Cytokine prodrugs and dual-prodrugs |
| KR20260017503A (ko) * | 2020-02-14 | 2026-02-05 | 길리애드 사이언시즈, 인코포레이티드 | Ccr8에 결합하는 항체 및 융합 단백질, 및 이의 용도 |
| JP7773991B2 (ja) | 2020-03-23 | 2025-11-20 | ザイムワークス ビーシー インコーポレイテッド | マスクされたｉｌ１２融合タンパク質及びその使用方法 |
-
2021
- 2021-03-31 AU AU2021248919A patent/AU2021248919A1/en active Pending
- 2021-03-31 US US17/995,162 patent/US20230159603A1/en active Pending
- 2021-03-31 WO PCT/US2021/025107 patent/WO2021202678A1/en not_active Ceased
- 2021-03-31 JP JP2022560206A patent/JP7771076B2/ja active Active
- 2021-03-31 CA CA3172641A patent/CA3172641A1/en active Pending
- 2021-03-31 MX MX2022012312A patent/MX2022012312A/es unknown
- 2021-03-31 TW TW110112013A patent/TWI906278B/zh active
- 2021-03-31 KR KR1020227037411A patent/KR20220161405A/ko active Pending
- 2021-03-31 IL IL296913A patent/IL296913A/en unknown
- 2021-03-31 BR BR112022019708A patent/BR112022019708A2/pt unknown
- 2021-03-31 EP EP21781122.3A patent/EP4126249A4/en active Pending
- 2021-03-31 CN CN202180038975.1A patent/CN115734806A/zh active Pending
- 2021-03-31 PH PH1/2022/552632A patent/PH12022552632A1/en unknown
-
2025
- 2025-11-05 JP JP2025186059A patent/JP2026048631A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7771076B2 (ja) | 2025-11-17 |
| JP2023520518A (ja) | 2023-05-17 |
| EP4126249A1 (en) | 2023-02-08 |
| EP4126249A4 (en) | 2024-04-24 |
| CN115734806A (zh) | 2023-03-03 |
| TW202204386A (zh) | 2022-02-01 |
| BR112022019708A2 (pt) | 2022-12-20 |
| KR20220161405A (ko) | 2022-12-06 |
| AU2021248919A1 (en) | 2022-10-13 |
| US20230159603A1 (en) | 2023-05-25 |
| TWI906278B (zh) | 2025-12-01 |
| MX2022012312A (es) | 2023-02-09 |
| PH12022552632A1 (en) | 2023-01-04 |
| WO2021202678A1 (en) | 2021-10-07 |
| IL296913A (en) | 2022-12-01 |
| JP2026048631A (ja) | 2026-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3172641A1 (en) | Masked il-12 cytokines and their cleavage products | |
| JP7735306B2 (ja) | マスクされたｉｌ－２サイトカイン及びその切断産物 | |
| US11718655B2 (en) | Masked interleukin-12 polypeptides | |
| US20230331799A1 (en) | Masked il-15 cytokines and their cleavage products | |
| US12280120B2 (en) | Tumor-specific cleavable linkers | |
| US20260115302A1 (en) | Tumor-specific cleavable linkers | |
| HK40092028A (zh) | 掩蔽的il-2细胞因子和其切割产物 | |
| HK40090912A (zh) | 掩蔽的il-15细胞因子和其切割产物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250116 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250116 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250116 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250117 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250117 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250117 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250117 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250307 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250307 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250307 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250429 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250505 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST Effective date: 20251114 Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST Effective date: 20251114 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251114 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260203 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260203 |